Medical breakthroughs, approvals and research that could change care.
The FDA approved GSK's Hibsago (bepirovirsen) on Oct. 20 for certain adults with chronic hepatitis B. In two phase 3 trials, 19% kept the virus under control 24 weeks after stopping all treatment. Here's who it's for and what the catch is.
A new study in Cell found taurine levels rise with age in people, immune cells release up to 80% of theirs before an inflammatory alarm, and extra taurine improved signs of healthy aging in old mice. It hasn't been tested as a treatment in people.
Merck and Moderna's investigational mRNA shot intismeran, added to Keytruda after melanoma surgery, lowered the risk of the cancer returning or death by 42% versus Keytruda alone in the phase 3 INTerpath-001 trial. It is not approved yet, and survival data are still coming.
